BMY - Altimmune COVID Update And Other News: The Good Bad And Ugly Of Biopharma

Altimmune provides positive updates for AdCOVID

Altimmune Inc. (ALT) reported positive data from the preclinical studies of its lead vaccine candidate, AdCOVID. The company is carrying out these studies as part of its collaboration with the University of Alabama at Birmingham for developing a vaccine against COVID-19.

The data from the latest study demonstrated potent stimulation of antigen-specific CD4+ and CD8+ T cells in the lungs of CD-1 mice. The impact was visible as early as within 10 days of administering a single intranasal vaccination. The responses were strongly biased toward CD8+ T